Skip to main content
. Author manuscript; available in PMC: 2014 Sep 12.
Published in final edited form as: Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459

Figure 4. Targeting GRAMD1B for ovarian cancer treatment.

Figure 4

(a) A Venn diagram for identification of novel targets for the treatment of ovarian cancer. (b) Expression of GRAMD1B, RBBP6, and SLC23A1, in a panel of chemosensitive and chemoresistant ovarian cancer cell lines. (c) Protein expression of GRAMD1B in taxane-sensitive (HeyA8 and SKOV3ip1) and taxane-resistant (HeyA8-MDR and SKOV3-TR) ovarian cancer cells (n=1). Effect of GRAMD1B downregulation on (d) cell viablity and (e) apoptosis in HeyA8-MDR cells. (f) Effect of knockdown of GRAMD1B on the sensitivity of HeyA8-MDR cells to paclitaxel or docetaxel treatment. Cell viability is expressed as a percentage of that measured in siRNA monotherapy treated wells. (g) Effect of GRAMD1B protein expression on overall survival in ovarian cancer patients (n=156). Scale bar represents 100 μm. [P-values obtained with (a-f) Student’s t-test or (g) log-rank test; (b) ***, P<0.001 or ****, P<0.0001; compared to the corresponding chemosensitive cell line; (d, e, f) *, P<0.05 or **, P<0.01; compared to cells treated with siCon; bars and error bars represent mean values and the corresponding S.E.M.s (n=3)].